Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5290 dose-ranging study in moderately to severely active ulcerative colitis
2022-501119-14-01Phase 2Authorised
- Sponsor
- Gilead Sciences
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of tilpisertib fosmecarbil in autoimmune colitis (3 arms), sponsored by Gilead Sciences. Primary endpoint: Clinical Response at Week 12. Planned start Apr 2024; status: authorised.
02
Drugs
tilpisertib fosmecarbil
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-501119-14-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501119-14-01.